In order to maintain the efficacy of CAR‐T therapy for longer, we need to explore the methods of further therapy after anti‐BCMA CAR‐T therapy in R/R MM patients with EM‐E. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.